Alzheimer's & dementia (Amsterdam, Netherlands) · 2026
Biomarkers for Alzheimer's disease to differentiate normal, SCD, and MCI subjects and their correlation with cognitive function.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Boutajangout Allal, Osorio Ricardo S, Masurkar Arjun V, Debure Ludovic, Ghuman Mobeena, Ahmed Wajiha, Pirraglia Elizabeth, Vedvyas Alok, Links Jon, Vega Brianna, Marsh Karyn, Chodosh Joshua, Shao Yongzhao, Wisniewski Thomas
Аннотация
INTRODUCTION: We assessed plasma biomarkers for the diagnosis of early Alzheimer's disease (AD).
METHODS: Subjects were divided into three groups: cognitively unimpaired (CU) (without subjective cognitive decline [SCD]) (n = 113), CU with SCD (n = 152), and mild cognitive impairment (MCI, n = 45). Plasma assays for amyloid beta (Aβ) 40, Aβ42, neurofilament light chain protein, glial fibrillary acidic protein, and phosphorylated tau181 levels were measured using single molecule array (Simoa) technology. Neuroinflammation and blood-brain barrier (BBB) biomarkers were measured using the Corplex cytokine 10-Plex kit and the angiogenesis 6-Plex kit, respectively.
RESULTS: Biomarker levels were regressed by cognitive group, age, sex, race, and apolipoprotein E apoE ε4 status, yielded significant positive associations between age and numerous AD, neuroinflammation, cytokine, and BBB plasma markers.
DISCUSSION: Linear regression analysis, adjusted for age, sex, race, and ApoE status, revealed significant differences between cognitive groups in levels of several plasma biomarkers and associations with age and sex. Neuroinflammation and BBB dysfunction showed significant positive associations with age across different stages of AD.
METHODS: Subjects were divided into three groups: cognitively unimpaired (CU) (without subjective cognitive decline [SCD]) (n = 113), CU with SCD (n = 152), and mild cognitive impairment (MCI, n = 45). Plasma assays for amyloid beta (Aβ) 40, Aβ42, neurofilament light chain protein, glial fibrillary acidic protein, and phosphorylated tau181 levels were measured using single molecule array (Simoa) technology. Neuroinflammation and blood-brain barrier (BBB) biomarkers were measured using the Corplex cytokine 10-Plex kit and the angiogenesis 6-Plex kit, respectively.
RESULTS: Biomarker levels were regressed by cognitive group, age, sex, race, and apolipoprotein E apoE ε4 status, yielded significant positive associations between age and numerous AD, neuroinflammation, cytokine, and BBB plasma markers.
DISCUSSION: Linear regression analysis, adjusted for age, sex, race, and ApoE status, revealed significant differences between cognitive groups in levels of several plasma biomarkers and associations with age and sex. Neuroinflammation and BBB dysfunction showed significant positive associations with age across different stages of AD.